within Pharmacolibrary.Drugs.ATC.D;

model D06BX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.0005,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Ingenol mebutate is a diterpene ester derived from the plant Euphorbia peplus. It is used topically for the treatment of actinic keratosis, a precancerous skin lesion caused by sun exposure. Due to safety concerns, it has been withdrawn in some regions (e.g., EU) from the market. It is not widely used today.</p><h4>Pharmacokinetics</h4><p>No conventional systemic pharmacokinetic parameters are available as per published literature, since ingenol mebutate is used topically and exhibits minimal systemic absorption in healthy adult subjects with actinic keratosis.</p><h4>References</h4><ol><li><p>Stockfleth, E, &amp; Bastian, M (2018). Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis. <i>Expert opinion on drug metabolism &amp; toxicology</i> 14(9) 911–918. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2018.1508449&quot;>10.1080/17425255.2018.1508449</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30074409/&quot;>https://pubmed.ncbi.nlm.nih.gov/30074409</a></p></li><li><p>Gras, J (2013). Ingenol mebutate: a new option for actinic keratosis treatment. <i>Drugs of today (Barcelona, Spain : 1998)</i> 49(1) 15–22. DOI:<a href=&quot;https://doi.org/10.1358/dot.2013.49.1.1910723&quot;>10.1358/dot.2013.49.1.1910723</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23362492/&quot;>https://pubmed.ncbi.nlm.nih.gov/23362492</a></p></li><li><p>Saraiva, MIR, et al., &amp; Westin, AT (2018). Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects. <i>Anais brasileiros de dermatologia</i> 93(4) 529–534. DOI:<a href=&quot;https://doi.org/10.1590/abd1806-4841.20186982&quot;>10.1590/abd1806-4841.20186982</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30066759/&quot;>https://pubmed.ncbi.nlm.nih.gov/30066759</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D06BX02;
